Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant Pharmaceuticals International, a multinational specialty pharmaceutical company, has closed on its exclusive worldwide collaboration agreement with GlaxoSmithKline for the investigational drug retigabine, a neuronal potassium channel opener for the treatment of adult epilepsy patients with refractory partial onset seizures.
Subscribe to our email newsletter
Under the terms of the agreement, Valeant received an upfront payment of $125 million from GlaxoSmithKline (GSK).
Valeant develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology.